QPPV.COM KNOWLEDGE ASSESSMENT

Upadacitinib: Discovery, Development, Safety and Pharmacovigilance โ€” Knowledge Assessment

Test your understanding of the concepts covered by Upadacitinib: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which interpretation of the Crohn's disease maintenance results from U-ENDURE is methodologically sound?
Question 2 of 10 Which interpretation best reflects the therapeutic rationale and pharmacological selectivity of upadacitinib?
Question 3 of 10 A patient with inflammatory bowel disease develops acute abdominal symptoms while taking upadacitinib, corticosteroids and an NSAID. Which case detail is especially important before classifying the event as gastrointestinal perforation?
Question 4 of 10 A patient develops pulmonary embolism while receiving upadacitinib shortly after surgery and has a previous thrombosis. What is the most appropriate pharmacovigilance interpretation?
Question 5 of 10 A patient is exposed to upadacitinib during pregnancy. Which information is most useful for an initial pharmacovigilance follow-up?
Question 6 of 10 After a new indication is authorised, the number of spontaneous reports for upadacitinib increases. Which first interpretation is most defensible?
Question 7 of 10 Under the EU JAK-inhibitor restrictions described in the article, which patient group is subject to a 'use only where suitable alternatives are unavailable' restriction?
Question 8 of 10 What is the appropriate role of spontaneous-report disproportionality analysis in upadacitinib surveillance?
Question 9 of 10 Why should medication reconciliation after a treatment switch include the timing of the previous biologic and corticosteroid exposure?
Question 10 of 10 How should the EU 2026 extensions for alopecia areata and non-segmental vitiligo be handled when reviewing the cited US 2025 prescribing information?

Select an answer to continue.

QPPV.com